Roots Analysis has done a detailed study on RNAi
Therapeutics Market (2nd Edition), 2019-2030, covering key
aspects of the industry’s evolution and identifying potential future growth
opportunities.
To order this 350+ page report, which features 130+ figures
and 190+ tables, please visit this https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html
Key Market Insights
§
Over 32,000 patents related to RNAi therapeutics,
indicating the heightened pace of research, have been filed / granted in the
last several years
§
Presently, there is only one approved drug and over 150
product candidates, which are being evaluated for the treatment of a variety of
disease indications, based on the RNAi principle
§
In order to achieve a competitive edge, the drug developers
are increasingly focusing on developing the robust pipeline molecules across
different therapeutic areas
§
Majority of the candidate therapies are currently in the
early stages of development and are based on the siRNA approach; the innovation
in this domain is being led by developers headquartered in the US
§
Several trials evaluating various
RNAi drug candidates against a wide range of therapeutic indications have been
registered in the recent past
§
Investors, having realized the opportunity within this
emerging segment of the pharmaceutical industry, have invested over USD 5
billion in capital across 65 instances, in the period between 2014 and 2019
§
The increasing interest in this
field is reflected in recent partnership activity; majority of deals inked were
R&D and licensing agreements, featuring the participation of both
international and indigenous stakeholders
§
In order to keep patients and healthcare professionals
informed and aware of the developments in this field of medicine, companies are
deploying diverse promotional strategies for their respective products
§
Prevalent trends indicate that the market for RNAi
therapeutics is poised to grow significantly as multiple late stage molecules
are commercialized in the near future, for the treatment of different clinical
conditions
For
more information, please visit https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html
Table of Contents
1 PREFACE
1.1. Scope of the
Report
1.2. Research
Methodology
1.3. Chapter
Outlines
2 EXECUTIVE
SUMMARY
3 INTRODUCTION
3.1. Chapter
Overview
3.2. Historical
Trends
3.2.1. Discovery of
RNAi
3.2.2. RNAi Therapy
Development Efforts
3.3. Mechanism of
RNAi
3.3.1. Components of
RNAi
3.3.2. Cellular
Mechanism
3.4. Types of RNAi
Molecules
3.4.1. siRNA
3.4.2. miRNA
3.4.3. shRNA
3.5. Applications
of RNAi
3.6. Advantages
and Disadvantages of RNAi
3.7. Regulatory
Guidelines
3.8. Future
Perspectives
4 COMPETITIVE
LANDSCAPE
4.1. Chapter
Overview
4.2. Marketed and Development
Pipeline
4.2.1. Analysis by
Type of RNAi Molecule
4.2.2. Analysis by
Phase of Development
4.2.3. Analysis by
Type of Target Gene
4.2.4. Analysis by
Therapeutic Area
4.2.5. Analysis by
Route of Administration
4.2.6. Analysis by
Special Drug Designation
4.2.7. Key Players
4.3. Developer
Landscape
4.3.1. Analysis by
Year of Establishment
4.3.2. Analysis by
Company Size
4.3.3. Analysis by
Location of Headquarters
5 COMPANY
COMPETITIVENESS ANALYSIS
5.1. Chapter
Overview
5.2. Methodology
5.3. Assumptions
and Key Parameters
5.4. Competitiveness
Analysis
6 LATE STAGE
RNAi THERAPEUTICS
6.1. Chapter
Overview
6.2. Onpattro®
6.2.1. Drug Overview
6.2.2. Technology
Overview
6.2.3. Current
Development Status
6.2.4. Recent
Clinical Trial Results
6.3. ARO-AAT
6.3.1. Drug Overview
6.3.2. Technology
Overview
6.3.3. Current
Development Status
6.3.4. Recent
Clinical Trial Results
6.4. Fitusiran
6.4.1. Drug Overview
6.4.2. Technology
Overview
6.4.3. Current
Development Status
6.4.4. Recent
Clinical Trial Results
6.5. Givosiran
6.5.1. Drug Overview
6.5.2. Technology
Overview
6.5.3. Current
Development Status
6.5.4. Recent
Clinical Trial Results
6.6. Inclisiran
6.6.1. Drug Overview
6.6.2. Technology
Overview
6.6.3. Current
Development Status
6.6.4. Recent
Clinical Trial Results
6.7. Lumasiran
6.7.1. Drug Overview
6.7.2. Technology
Overview
6.7.3. Current
Development Status
6.7.4. Recent
Clinical Trial Results
6.8. QPI-1002
6.8.1. Drug Overview
6.8.2. Technology
Overview
6.8.3. Current
Development Status
6.8.4. Recent
Clinical Trial Results
6.9. SYL 1001
6.9.1. Drug Overview
6.9.2. Technology
Overview
6.9.3. Current
Development Status
6.9.4. Recent
Clinical Trial Results
6.10. Vigil-EWS
6.10.1. Drug Overview
6.10.2. Technology
Overview
6.10.3. Current
Development Status
6.10.4. Recent
Clinical Trial Results
6.11. Vutrisiran
6.11.1. Drug Overview
6.11.2. Technology
Overview
6.11.3. Current
Development Status
6.11.4. Recent
Clinical Trial Results
7 TECHNOLOGY
PLATFORMS AND DELIVERY SYSTEMS
7.1. Chapter
Overview
7.2. Key
Components of RNAi Delivery Systems
7.2.1. RNAi Triggers
7.2.1.1. Asymmetric
siRNA (cp-siRNA)
7.2.1.2. DNA Directed
RNAi (ddRNAi)
7.2.1.3. Dicer
Substrate siRNA (DsiRNA)
7.2.1.4. Naked siRNA
7.2.1.5. Self-Deliverable
RNA (sd-RNA)
7.2.1.6. Self-Deliverable
rxRNA (sd-rxRNA)
7.2.1.7. Unlocked
Nucleobase Analog (UNA) Containing siRNA (UsiRNA)
7.2.2. RNAi Delivery
Technologies
7.2.2.1. Cationic
Liposomes
7.2.2.2. Lipid Based
Nanoparticle
7.2.2.3. Polymer Based
Nanoparticles
7.2.2.4. Conjugated
Delivery Systems
8 KEY
THERAPEUTIC INDICATIONS
8.1. Chapter
Overview
8.2. Oncological
Disorders
8.2.1. Analysis by
Target Indication
8.2.2. Analysis by
Type of RNAi Molecule
8.3. Infectious
Diseases
8.3.1. Analysis by
Target Indication
8.3.2. Analysis by
Type of RNAi Molecule
8.4. Genetic
Disorders
8.4.1. Analysis by
Target Indication
8.4.2. Analysis by
Type of RNAi Molecule
8.5. Ophthalmic
Diseases
8.5.1. Analysis by Target
Indication
8.5.2. Analysis by
Type of RNAi Molecule
8.6. Respiratory
Disorders
8.6.1. Analysis by
Target Indication
8.6.2. Analysis by
Type of RNAi Molecule
9 CLINICAL
TRIAL ANALYSIS
9.1. Chapter
Overview
9.2. Scope and
Methodology
9.3. RNAi Therapeutics:
Clinical Trial Analysis
9.3.1. Analysis by
Trial Registration Year
9.3.2. Analysis by
Trial Phase
9.3.3. Analysis by
Recruitment Status
9.3.4. Analysis by
Type of Sponsor / Collaborator
9.3.5. Analysis by
Type of RNAi Molecule
9.3.6. Analysis by Therapeutic
Area
9.3.7. Geographical
Analysis by Number of Clinical Trials
9.3.8. Geographical
Analysis by Number of Clinical Trials, Trial Phase and Recruitment Status
9.3.9. Geographical
Analysis by Number of Clinical Trials and Type of RNAi Molecule
9.3.10. Geographical
Analysis by Number of Clinical Trials, Type of RNAi Molecule and Trial Phase
9.3.11. Geographical
Analysis by Number of Clinical Trials and Therapeutic Area
9.3.12. Geographical
Analysis by Number of Clinical Trials, Therapeutic Area and Trial Phase
9.3.13. Analysis of
Enrolled Patient Population by Location of Trial
9.3.14. Analysis of
Enrolled Patient Population by Trial Phase and Recruitment Status
9.3.15. Analysis of
Enrolled Patient Population by Type of RNAi Molecule and Location of Trial
9.3.16. Analysis of
Enrolled Patient Population by Type of RNAi Molecule, Trial Phase and Location
of Trial
9.3.17. Analysis of
Enrolled Patient Population by Therapeutic Area and Location of Trial
9.3.18. Analysis of
Enrolled Patient Population by Therapeutic Area, Trial Phase and Location of
Trial
9.4. Concluding
Remarks
9.4.1. Key
Therapeutic Candidates
9.4.2. Key Clinical
Trials
10 PATENT
ANALYSIS
10.1. Chapter
Overview
10.2. Scope and
Methodology
10.3. RNAi
Therapeutics: Patent Analysis
10.3.1. Analysis by
Publication Year
10.3.2. Analysis by
Patent Status
10.3.3. Analysis by
CPC Code
10.3.4. Analysis by
Type of Organization
10.3.5. Analysis by
Geographical Coverage
103.6. Emerging Focus
Area
10.3.7. Leading
Players: Analysis by Number of Patents
10.4. RNAi
Therapeutics: Patent Benchmarking Analysis
10.4.1. Analysis by
Key Patent Characteristics
10.5. RNAi
Therapeutics: Patent Valuation Analysis
11 RECENT
PARTNERSHIPS
11.1. Chapter
Overview
11.2. Partnership
Models
11.3. RNAi
Therapeutics: Recent Partnerships
11.3.1. Analysis by
Year of Partnership
11.3.2. Analysis by
Type of Partnership
11.3.3. Analysis by
Type of RNAi Molecule
11.3.4. Analysis by
Duration of Partnership
11.3.5. Analysis by
Therapeutic Area
11.3.6. Most Active
Players: Analysis by Number of Partnerships
11.3.7. Regional
Analysis
11.3.7.1. Country-wise
Distribution
11.3.7.2. Intercontinental
and Intracontinental Deals
12 FUNDING AND
INVESTMENT ANALYSIS
12.1. Chapter
Overview
12.2. Types of
Funding
12.3. RNAi
Therapeutics: Funding and Investment Analysis
12.3.1. Analysis by
Cumulative Funding Instances, 2014-2019
12.3.2. Analysis by
Amount Invested
12.3.3. Analysis by
Type of Funding
12.3.4. Analysis by
Year and Type of Funding
12.3.5. Analysis by
Amount Invested across Different Types of RNAi Molecules
12.3.6. Regional
Analysis by Amount Invested
12.3.7. Most Active
Players
12.3.8. Key Investors
12.4. Concluding
Remarks
13 PROMOTIONAL
ANALYSIS
13.1. Chapter
Overview
13.2. Overview of Channels
used for Promotional Campaigns
13.3. Summary:
Product Website Analysis
13.3.1. Summary:
Patient Support Services and Informative Downloads
13.4. Promotional
Analysis: EXONDYS 51® (Eteplirsen)
13.4.1. Drug Overview
13.4.2. Product
Website Analysis
13.4.2.1. Message for
Healthcare Professionals
13.4.2.2. Message for
Patients
13.4.2.3. Patient
Assistance Program (SareptAssist)
13.4.2.4. Additional
Information
13.4.3. Other
Promotional Strategies
13.5. Promotional
Analysis: Defitelio®
13.5.1. Drug Overview
13.5.2. Product
Website Analysis
13.5.2.1. Message for
Healthcare Professionals
13.5.2.2. Message for
Patients
13.5.2.3. Additional
Information
13.5.3. Other
Promotional Strategies
13.6. Promotional
Analysis: Onpattro®
13.6.1. Drug Overview
13.6.2. Product
Website Analysis
13.6.2.1. Message for
Healthcare Professionals
13.6.2.2. Message for
Patients
13.6.2.3. Patient
Assistance Program – Alnylam Assist
13.6.2.4. Additional
Information
13.6.3. Other
Promotional Strategies
14 MARKET
SIZING AND OPPORTUNITY ANALYSIS
14.1. Chapter
Overview
14.2. Scope and
Limitations
14.3. Key
Assumptions and Forecast Methodology
14.4. Overall RNAi
Therapeutics Market, 2019-2030
14.4.1. RNAi
Therapeutics Market: Analysis by Type of RNAi Molecule
14.4.2. RNAi
Therapeutics Market: Analysis by Therapeutic Area
14.4.3. RNAi
Therapeutics Market: Analysis by Route of Administration
14.4.4. RNAi
Therapeutics Market: Share of Leading Players
14.4.5. RNAi
Therapeutics Market: Analysis by Geography
14.5. RNAi
Therapeutics Market: Value Creation Analysis
14.6. RNAi
Therapeutics Market: Product-wise Sales Forecasts
14.6.1. Onpattro®
14.6.1.1. Target Patient
Population
14.6.1.2. Sales Forecast
14.6.1.3. Net Present
Value
14.6.1.4. Value Creation
Analysis
14.6.2. ARO-AAT
14.6.2.1. Target Patient
Population
14.6.2.2. Sales Forecast
14.6.2.3. Net Present
Value
14.6.2.4. Value Creation
Analysis
14.6.3. Fitusiran
14.6.3.1. Target Patient
Population
14.6.3.2. Sales Forecast
14.6.3.3. Net Present
Value
14.6.3.4. Value Creation
Analysis
14.6.4. Givosiran
14.6.4.1. Target Patient
Population
14.6.4.2. Sales Forecast
14.6.4.3. Net Present
Value
14.6.4.4. Value Creation
Analysis
14.6.5. Inclisiran
14.6.5.1. Target Patient
Population
14.6.5.2. Sales Forecast
14.6.5.3. Net Present
Value
14.6.5.4. Value Creation
Analysis
14.6.6. Lumasiran
14.6.6.1. Target Patient
Population
14.6.6.2. Sales Forecast
14.6.6.3. Net Present
Value
14.6.6.4. Value Creation
Analysis
14.6.7. QPI-1002
14.6.7.1. Target Patient
Population
14.6.7.2. Sales Forecast
14.6.7.3. Net Present
Value
14.6.7.4. Value Creation
Analysis
14.6.8. SYL 1001
14.6.8.1. Target Patient
Population
14.6.8.2. Sales Forecast
14.6.8.3. Net Present
Value
14.6.8.4. Value Creation
Analysis
14.6.9. Vigil-EWS
14.6.9.1. Target Patient
Population
14.6.9.2. Sales Forecast
14.6.9.3. Net Present
Value
14.6.9.4. Value Creation
Analysis
14.6.10. Vutrisiran
14.6.10.1. Target Patient
Population
14.6.10.2. Sales Forecast
14.6.10.3. Net Present
Value
14.6.10.4. Value Creation
Analysis
15 RNAi
IN DIAGNOSTICS
15.1. Chapter
Overview
15.2. Key
Characteristics of a Biomarker
15.3. Circulating
miRNA Biomarkers
15.4. miRNA
Biomarkers in Oncological Disorders
15.4.1. Importance of
Early Cancer Detection
15.4.2. Cancer
Screening and Diagnosis
15.4.3. Conventional
Cancer Diagnostics
15.4.4. Need for
Non-Invasive Approaches
15.4.5. Key
Indications
15.4.5.1. Prostate Cancer
15.4.5.2. Breast Cancer
15.4.5.3. Lung Cancer
15.4.5.4. Colorectal
Cancer
15.4.5.5. Gastric Cancer
15.4.5.6. Hematological
Cancer
15.5. miRNA
Biomarkers in Cardiovascular Diseases
15.5.1. Key
Indications
15.5.1.1. Myocardial
Infarction (MI)
15.5.1.2. Coronary Artery
Disease (CAD)
15.6. miRNA Based
Diagnostic Tests
16 SERVICE
PROVIDERS FOR RNAi THERAPEUTICS
16.1. Chapter
Overview
16.2. List of
Service Providers
16.2.1. Analysis by
Type of Service Provider
16.2.2. Analysis by
Location of Service Provider
16.2.3. Analysis by
Type of RNAi Molecule
17 SWOT
ANALYSIS
17.1. Overview
17.2. Strengths
17.3. Weaknesses
17.4. Opportunities
17.5. Threats
17.6 Concluding
Remarks
18 CONCLUSION
18.1. Chapter
Overview
18.2. Key Takeaways
19 INTERVIEW TRANSCRIPT(S)
20 APPENDIX
1: TABULATED DATA
21 APPENDIX 2: LIST OF
COMPANIES AND ORGANIZATIONS
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
